For younger patients with an acute lymphoblastic leukemia (ALL) subtype, modifying treatment based on chemotherapy response can make a vital difference.
Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.
Tyrosine kinase inhibitors (TKIs) may be effective for the treatment of acute lymphoblastic leukemia (ALL).
Many young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and could benefit from drugs used to treat other types of leukemia.
Weekend hospital admission for pediatric patients with newly diagnosed leukemia is associated with a longer length of stay, slightly longer wait to start chemotherapy, and higher risk for respiratory failure.
CPI-613 safe and somewhat efficacious for the treatment of patients with relapsed or refractory leukemia.
A select team of immune-system cells from patients with leukemia can be multiplied in the laboratory, creating a horde of natural killer cells that can be used to target and destroy the cancer cells.
By analyzing the DNA sequence of patients at different stages of leukemia, researchers have discovered mutations in genes that lead to childhood leukemia of the acute lymphoblastic type, the most common childhood cancer.
Weekend admission for pediatric patients with leukemia associated with a longer length of stay.
The EUROCARE study, the largest population-based study of survival in European blood cancer patients to date, analyzed data from 30 cancer registries, involving all patients with cancer diagnoses in 20 European countries.
Scientists have developed a test which accurately predicts the prognosis for patients with the most common form of leukemia.
An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.
Scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast cancer.
Cancer cells decide whether to live or die after a short period of intense exposure to targeted therapy, opposing the current requirement for continuous treatment, according to a new study.
Researchers in Melbourne, Australia, have shown that switching off a gene called Pax5 could cause a type of leukemia, and restoring its function could cure the disease.
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
Loss of JAK2, a protein that can promotes the growth of cancer cells, causes healthy blood stem cells to disappear while cancer cells preserve their growth potential, according to research.
By targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, according to new research.
A team of investigators has uncovered a connection between Down syndrome and a heightened risk of developing acute lymphoblastic leukemia during childhood.
Clinical trials for a new experimental drug, CPX-351, to treat acute myeloid leukemia are very promising, according to researchers.
The experimental compound dubbed TTT-3002 has been identified as a potent means to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia, according to research.
Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.
Patients with terminal forms of leukemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects.
A German study of a new drug therapy for chronic lymphocytic leukemia was praised because the majority of the patients enrolled were elderly and had other, coexisting health issues.
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88% achieved complete remission after being treated with genetically modified versions of their own immune cells.
A group of researchers discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.
Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, has also proved successful in treating hairy cell leukemia.
Linear dose-response relationship for acute lymphoblastic leukemia and acute myeloid leukemia has been observed.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|